02283nas a2200469   4500000000100000008004100001260001300042653002400055653002600079653002400105653001600129653001200145653003000157653003800187653001100225653002300236653002100259653002000280653002300300653001200323653002500335653002600360653002500386653001300411653001500424100001100439700001400450700001500464700001100479700001500490700001100505700001300516700001500529700001100544700001300555245009600568856004100664300001100705490000700716520107600723022001401799       1994                            d  c1994 Sep10aAgglutination Tests10aAntibodies, Bacterial10aAntigens, Bacterial10aClofazimine10aDapsone10aDrug Therapy, Combination10aEnzyme-Linked Immunosorbent Assay10aHumans10aImmunity, Cellular10aImmunoglobulin M10aImmunoglobulins10aLeprostatic Agents10aleprosy10aLongitudinal studies10aLymphocyte Activation10aMycobacterium leprae10aRifampin10aSkin Tests1 aVu T T1 aHoang T L1 aNguyen D Q1 aHo M L1 aNguyen D H1 aLe T H1 aDang D T1 aNguyen Q A1 aLe T P1 aTran H K00aLong-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.  uhttp://ila.ilsl.br/pdfs/v62n3a04.pdf  a365-730 v623 a<p>A long-term survey of leprosy patients of all clinical types, starting at the time of diagnosis, was carried out to monitor clinical, bacteriological and immunological parameters at regular intervals during multiple drug therapy (MDT). The patients were assigned to two groups for treatment following WHO guidelines: paucibacillary (PB) and multibacillary (MB). Immunoglobulin levels, specific antibodies, skin-test responses to different soluble mycobacterial antigens (new tuberculins), and in vitro proliferative responses to mitogens and to antigens were measured during treatment, as were clinical changes, the bacterial index, and clinical improvement. No exact relations between disease activity and IgM antibody levels, both IgM immunoglobulin and specific IgM antibody to a species-specific antigen (ND-O-BSA), could be seen for MB patients. Changes in in vitro cell-mediated immunity and skin-test response seemed to be more directly related to the bacterial load and could reflect the improvement of bacteriological and clinical parameters during MDT.</p>
  a0148-916X